Bones and Joints | Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Pediatrics | Phase I, Phase I-II
A Phase 1/2 Platform Study to Evaluate the Safety and Efficacy of Investigational Agents in Pediatric and Young Adult Participants with Hematologic Malignancies or Solid Tumors
Volunteers
Health Professionals
What is the purpose of this trial?
Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL)/Burkitt lymphoma, or neuroblastoma and in pediatric and young adult participants with Ewing sarcoma.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Aron Flagg, MD
- Asher Marks, MD
- Claudia Auerbach, APRN
- Juan Vasquez, MD
- Kate Hallissey
- Lakshmanan Krishnamurti, MD
- Mary Jane Hogan, MD, MPH, FAAP
- Michaela Russell
- Nitya Bakshi, MBBS, MS
- Prasanna Ananth, MD, MPH
- Rozalyn Levine Rodwin, MD, MHS
- Stephanie Massaro, MD, MPH
- Stephanie Prozora, MD
- Vidya Puthenpura, MD, MHS, FAAP
- Last Updated11/22/2024
- Study HIC#2000036967